NEPHRON has obtained FDA approval for its Abbreviated New Drug Application (ANDA216254), paving the way for a generic entry that is expected to significantly undermine the market dominance of the reference brand through increased generic pricing. This regulatory clearance is anticipated to drive a swift loss of exclusivity for the branded product and reshape the revenue landscape for manufacturers in the therapeutic class.